JP6420247B2 - ゲムシタビンプロドラッグ及びその使用 - Google Patents

ゲムシタビンプロドラッグ及びその使用 Download PDF

Info

Publication number
JP6420247B2
JP6420247B2 JP2015542007A JP2015542007A JP6420247B2 JP 6420247 B2 JP6420247 B2 JP 6420247B2 JP 2015542007 A JP2015542007 A JP 2015542007A JP 2015542007 A JP2015542007 A JP 2015542007A JP 6420247 B2 JP6420247 B2 JP 6420247B2
Authority
JP
Japan
Prior art keywords
oxo
anilino
cancer
yield
difluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015542007A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503414A5 (enExample
JP2016503414A (ja
Inventor
アイ．ウー ローレンス
アイ．ウー ローレンス
Original Assignee
ボーイエン セラピューティクス，インコーポレイティド
ボーイエン セラピューティクス，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボーイエン セラピューティクス，インコーポレイティド, ボーイエン セラピューティクス，インコーポレイティド filed Critical ボーイエン セラピューティクス，インコーポレイティド
Publication of JP2016503414A publication Critical patent/JP2016503414A/ja
Publication of JP2016503414A5 publication Critical patent/JP2016503414A5/ja
Application granted granted Critical
Publication of JP6420247B2 publication Critical patent/JP6420247B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2015542007A 2012-11-13 2013-11-12 ゲムシタビンプロドラッグ及びその使用 Active JP6420247B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725643P 2012-11-13 2012-11-13
US61/725,643 2012-11-13
PCT/US2013/069640 WO2014078295A1 (en) 2012-11-13 2013-11-12 Gemcitabine prodrugs and uses thereof

Publications (3)

Publication Number Publication Date
JP2016503414A JP2016503414A (ja) 2016-02-04
JP2016503414A5 JP2016503414A5 (enExample) 2017-01-05
JP6420247B2 true JP6420247B2 (ja) 2018-11-07

Family

ID=50681903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015542007A Active JP6420247B2 (ja) 2012-11-13 2013-11-12 ゲムシタビンプロドラッグ及びその使用

Country Status (10)

Country Link
US (3) US8956613B2 (enExample)
EP (1) EP2919790B1 (enExample)
JP (1) JP6420247B2 (enExample)
KR (1) KR20150082606A (enExample)
CN (1) CN104968353B (enExample)
AU (1) AU2013345007B2 (enExample)
BR (1) BR112015010941A2 (enExample)
CA (1) CA2891124A1 (enExample)
SG (1) SG11201503773SA (enExample)
WO (1) WO2014078295A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078295A1 (en) 2012-11-13 2014-05-22 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
AU2015240465B2 (en) 2014-04-04 2020-02-27 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
WO2016078397A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物及其应用
WO2016078163A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物二聚体及其应用
WO2016078399A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 新型胞苷衍生物二聚体及其应用
ITUB20159671A1 (it) * 2015-12-22 2017-06-22 Maurizio Ceruti Carbammati lipidici di farmaci antitumorali
EP3738595A1 (en) * 2015-12-23 2020-11-18 Nucana PLC Combination therapy
CN106946960A (zh) * 2017-03-29 2017-07-14 郑州泰基鸿诺医药股份有限公司 一种吉西他滨前药的晶型、制备方法、用途和药物组合物
WO2018200859A1 (en) 2017-04-26 2018-11-01 Kalman Thomas I Multitargeted nucleoside derivatives
CN108329371B (zh) * 2018-03-06 2021-04-09 沈阳药科大学 白蛋白结合型吉西他滨前药及其合成和应用
AU2019258590B2 (en) * 2018-04-26 2022-09-08 NanoMed Holdings Pty Ltd Gemcitabine amphiphile prodrugs
GR1009958B (el) * 2019-04-24 2021-03-18 ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." Παραγωγα γεμσιταβινης και μεθοδοι δημιουργιας παραγωγων γεμσιταβινης
GB201906210D0 (en) 2019-05-02 2019-06-19 Econic Tech Limited A polyol block copolymer, compositions and processes therefor
GB201906214D0 (en) 2019-05-02 2019-06-19 Econic Tech Ltd A polyol block copolymer, compositions and processes therefor
CN114011581B (zh) * 2021-11-09 2023-03-24 昆明理工大学 一种弱酸性条件下铜硫分离的抑制剂制备方法及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814438A (en) 1986-12-24 1989-03-21 Eli Lilly And Company Immunoglobulin conjugates of 2',2'-difluronucleosides
US4994558A (en) 1986-12-24 1991-02-19 Eli Lilly And Company Immunoglobulin conjugates
WO1998032762A1 (en) 1997-01-24 1998-07-30 Norsk Hydro Asa Gemcitabine derivatives
GB2321454A (en) 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
GB0321613D0 (en) 2003-09-15 2003-10-15 Drug Discovery Lab As Compounds
FR2874016B1 (fr) 2004-06-30 2006-11-24 Centre Nat Rech Scient Cnrse Nanoparticules de derives de la gemcitabine
WO2006029081A2 (en) 2004-09-02 2006-03-16 Neopharm, Inc. Nucleoside-lipid conjugates, their method of preparation and uses thereof
WO2006030217A2 (en) 2004-09-15 2006-03-23 Drug Discovery Laboratory As Drug conjugates of long chain fatty acid or ester moieties as protein binding prodrugs
EP1831237B1 (en) 2004-12-17 2008-08-20 Eli Lilly And Company Amide prodrug of gemcitabine, compositions and use thereof
NO322682B1 (no) 2005-03-18 2006-11-27 Clavis Pharma Asa Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
AT502221A1 (de) 2005-07-20 2007-02-15 Pharmacon Forschung & Beratung Gmbh Homogemcitabine, verfahren zu ihrer herstellung sowie deren verwendung
EP2043653B1 (en) 2006-06-21 2013-12-25 Eli Lilly And Company Crystalline forms of gemcitabine amide prodrug, compositions and use thereof
CN101209350B (zh) 2006-12-30 2011-09-07 中国人民解放军军事医学科学院毒物药物研究所 以氨基酸为连接子的多聚谷氨酸-药物偶合物
WO2010039039A1 (en) 2008-10-03 2010-04-08 Clavis Pharma Asa Oral formulations of gemcitabine derivatives
US9434610B2 (en) 2008-10-07 2016-09-06 Rexahn Pharmaceuticals, Inc. HPMA—docetaxel conjugates and uses therefore
CN101525361B (zh) 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
EP2448408A4 (en) * 2009-07-02 2015-06-03 Kempharm Inc CONJUGATES OF PHENYLETHANOIC ACID, PHENYLPROPANOIC ACID AND PHENYLPROPENOIC ACID AND HYDROCODONE PRODRUGS, METHODS OF MAKING AND USING THEM
US20110281815A1 (en) 2009-11-20 2011-11-17 Clavis Pharma As Parental formulations of gemcitabine derivatives
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
WO2012098557A1 (en) 2011-01-20 2012-07-26 Institute Of Life Sciences Pegylated gemcitabine derivative and process for preparing the same
EP2739290A4 (en) 2011-08-02 2015-04-15 Clovis Oncology Inc METHOD FOR SELECTION OF CHEMOTHERAPEUTICS AGAINST ADENOCARCINOMAS
CN102432654A (zh) 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
WO2014078295A1 (en) 2012-11-13 2014-05-22 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
CN103130854A (zh) 2013-01-31 2013-06-05 华东师范大学 维生素e琥珀酸酯化吉西他滨前药及应用

Also Published As

Publication number Publication date
AU2013345007B2 (en) 2018-08-30
EP2919790A1 (en) 2015-09-23
WO2014078295A8 (en) 2015-05-21
KR20150082606A (ko) 2015-07-15
CN104968353A (zh) 2015-10-07
AU2013345007A1 (en) 2015-05-21
US9890189B2 (en) 2018-02-13
CN104968353B (zh) 2017-12-22
US8956613B2 (en) 2015-02-17
EP2919790B1 (en) 2018-04-04
CA2891124A1 (en) 2014-05-22
US20150132298A1 (en) 2015-05-14
US9540410B2 (en) 2017-01-10
JP2016503414A (ja) 2016-02-04
SG11201503773SA (en) 2015-06-29
US20140134160A1 (en) 2014-05-15
US20170107245A1 (en) 2017-04-20
WO2014078295A1 (en) 2014-05-22
EP2919790A4 (en) 2016-04-06
BR112015010941A2 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
JP6420247B2 (ja) ゲムシタビンプロドラッグ及びその使用
US11021510B2 (en) Prodrugs of clofarabine
ES2973442T3 (es) Moduladores de la vía integrada del estrés
TWI679201B (zh) 吡唑并嘧啶化合物
US20210230195A1 (en) Prodrug modulators of the integrated stress pathway
US20080311037A1 (en) Compounds which bind PSMA and uses thereof
US20100129363A1 (en) Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US20210323913A1 (en) Sigma receptor binders
JP6422936B2 (ja) ５−ブロモ−インジルビン
JP2013503888A (ja) 癌を治療するための化合物および組成物
US11198675B2 (en) DNA2 inhibitors for cancer treatment
US11701377B2 (en) Methods for treating cancers by prodrugs of clofarabine
US10646479B2 (en) Use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetrahydropyridine as a treatment for cancer
WO2005099824A1 (en) 1-glyoxylamide indolizines for treating lung and ovarian cancer
WO2025171226A1 (en) Compositions and methods for inducing ferroptosis
EP3324962A1 (en) Novel aminothiazole compounds and methods using same
WO2008016700A2 (en) N-oxide compounds for therapeutics uses
KR20090061356A (ko) 제니스테인을 포함하는 유방암 치료 및 예방용 조성물

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20150713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181011

R150 Certificate of patent or registration of utility model

Ref document number: 6420247

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R150 Certificate of patent or registration of utility model

Ref document number: 6420247

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250